Larger studies are needed because of the low numbers of patients on SGLT2 inhibitors in the FLOW trial, which showed the kidney benefits of GLP-1 receptor agonists.
, suggests that these benefits are consistent whether patients are or are not also treated with sodium-glucose cotransporter 2 inhibitors.
However, one of the most pressing questions the initial study left open was how the use of SGLT2 inhibitors, which is the standard treatment for patients with T2D and CKD, affect those outcomes. Mann noted that more than 80% of patients in the study on SGLT2 inhibitors at baseline remained on the drugs throughout the trial, and by the end of the trial, the percentage of patients on SGLT2 inhibitors had increased to 33%.
"The benefit of a GLP-1 receptor agonist on top of that probably needs another study to really drill a bit deeper on the issue."
Chronic Kidney Failure CKD - Chronic Kidney Disease Chronic Kidney Disease CKD Diabetes Mellitus Type 2 Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D SGLT2 Inhibitors Sodium-Glucose Transporter-2 Inhibitors Sodium-Glucose Co-Transporter-2 Inhibitors Sodium-Glucose Cotransporter-2 Inhibitors Kidneys Renal Failure Renal Insufficiency
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
SGLT2 Inhibitors Add to GLP-1s' Cardio, Kidney BenefitsThe largest analysis to date details added effects of SGLT2 inhibitors among those with type 2 diabetes when combined with GLP-1 receptor agonists.
Read more »
Gospel singer undergoes lifesaving kidney transplant after losing mom, 2 sisters who battled chronic kidney diseaseTammy Edwards said of her survival, 'The good news had to come our way.'
Read more »
Woman Who Received Pig Kidney Transplant Has It RemovedSurgeons at NYU took out the pig kidney because it wasn’t getting enough blood flow.
Read more »
Glucagon Blocker and SGLT2 Inhibitor: Winning Combo in T1D?Adding a glucagon receptor antagonist to SGLT2 inhibitor therapy improved glycemic control, reduced insulin use, and appeared to mitigate risk of diabetic ketoacidosis in patients with T1D.
Read more »
Helping Patients Navigate High Costs of GLP-1 MedicationsInjectable anti-obesity drugs can run close to $1000 per month, so patients rely on physicians to find affordable pharmacy options.
Read more »
Add-On to GLP-1s Yields Greater Weight LossCombination therapy of bupropion/naltrexone and GLP-1 receptor agonists showed a synergistic weight loss effect in individuals with obesity who responded poorly to GLP-1 monotherapy.
Read more »